While it is difficult to run a clinical trial in GBM with IDH mutation in a single institution since the incident rate is low, it may be beneficial to run a multisite trial to determine if GBM with IDH mutation are unusually sensitive to belinostat. The gene discussed is IDH1; the disease is glioblastoma.